Innoviva (INVA) Expected to Announce Quarterly Earnings on Thursday

Innoviva (NASDAQ:INVA) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $92.59 million for the quarter.

Innoviva (NASDAQ:INVA) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.57 earnings per share for the quarter. The firm had revenue of $91.81 million for the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Price Performance

NASDAQ INVA opened at $17.79 on Tuesday. The company has a market cap of $1.11 billion, a PE ratio of 25.78 and a beta of 0.55. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The firm’s 50-day simple moving average is $18.04 and its two-hundred day simple moving average is $18.85. Innoviva has a 52 week low of $14.32 and a 52 week high of $21.28.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Innoviva from a “buy” rating to a “hold” rating in a research note on Saturday, February 22nd.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.